HuMax-IL8: meta-analysis of COVID-19 studies

Meta-analysis1 study · 43 patientsc19early.org

HuMax-IL8 for COVID-19

Serious outcome risk
HuMax-IL8
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−6%
Mortality (1)−6%
ICU admission (1)−100%
RCTs (1)−6%
Late (1)−6%
00.511.5+
← HuMax-IL8
reduces risk
Increased
risk →
October 2026

HuMax-IL8 COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9
All studies−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.900.511.52+
Rotate screen for more detailsIncrease width for more details
← HuMax-IL8
reduces risk
HuMax-IL8
increases risk →
October 2026

HuMax-IL8 COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9
All studies−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.900.511.52+
Rotate screen for more detailsIncrease width for more details
← HuMax-IL8
reduces risk
HuMax-IL8
increases risk →
October 2026

HuMax-IL8 COVID-19 ICU results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−100%2.00 · 0.34–11.629/181/4100% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.45
All studies−100%2.00 · 0.34–11.629/181/4100% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.4500.511.52+
Rotate screen for more detailsIncrease width for more details
← HuMax-IL8
reduces risk
HuMax-IL8
increases risk →
October 2026

HuMax-IL8 COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9
All studies−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.900.511.52+
Rotate screen for more detailsIncrease width for more details
← HuMax-IL8
reduces risk
HuMax-IL8
increases risk →
October 2026

HuMax-IL8 COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Late treatment−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9
All studies−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.900.511.52+
Rotate screen for more detailsIncrease width for more details
← HuMax-IL8
reduces risk
HuMax-IL8
increases risk →
October 2026

HuMax-IL8 COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Late treatment−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.9
All studies−6%1.06 · 0.46–2.4711/295/146% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.900.511.52+
Rotate screen for more detailsIncrease width for more details
← HuMax-IL8
reduces risk
HuMax-IL8
increases risk →